

Reshma Ramachandran, MD, MPP

Reshma Ramachandran, MD, MPP is a health services researcher, family medicine physician, and National Clinician Scholars Program fellow at the Yale School of Medicine. Her research focuses on the realignment of incentives awarded to healthcare stakeholders including pharmaceutical companies, hospitals, and universities towards prioritizing equitable patient access to safe, effective health technologies. Specific to FDA regulatory policy, she has examined the application of medical countermeasure priority review vouchers, evidentiary basis for recent antimicrobial approvals, agency enforcement of clinical trial results reporting through an ongoing freedom of information act investigation, and therapeutic value of reformulations. Dr. Ramachandran's research has been published in high-impact peer-reviewed journals (e.g. *JAMA*, *JAMA Network Open*, *American Journal of Public Health*, *BMJ*). She has also authored several editorials related to regulatory and pharmaceutical policy in prominent media (e.g. *The New York Times*, *Washington Post*, *STAT News*, *CNN Opinion*). She also is a current Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) Scholar.

Prior to this role, Dr. Ramachandran worked as research faculty as part of the Innovation + Design Enabling Access (IDEA) Initiative at the Johns Hopkins Bloomberg School of Public Health. As part of the IDEA Initiative, she managed the Strategic Policy Program for ReAct-Action on Antibiotic Resistance, a global, independent, and interdisciplinary network supported by the Swedish International Development Cooperation Agency (Sida). In this role, she completed commissioned analyses and reports for the World Health Organization and other United Nations agencies and prepared policy briefs for national governments, non-governmental organizations, and other stakeholders towards shaping key agreements including the United Nations Political Declaration on Antimicrobial Resistance in September 2016. She has since continued to work with the ReAct Strategic Policy Program as a Senior Policy Scholar. Besides antimicrobial resistance, Dr. Ramachandran also engaged in efforts to lower high prescription drug prices, including working with state policymakers and other stakeholders in Maryland and other states to draft drug pricing transparency and price gouging legislation.

Dr. Ramachandran is trained in both medicine at the Alpert Medical School at Brown University and in public policy at the Harvard Kennedy School of Government. She completed her family medicine residency at Kaiser Permanente Los Angeles Medical Center and University of California, Los Angeles. Previously, she served as the first PharmFree Fellow with the American Medical Student Association (AMSA) focused on examining and addressing the undue influence of pharmaceutical companies on prescribing behavior and medical education. During this fellowship, she led efforts to enhance and expand a scorecard assessing conflict of interest policies of U.S. academic medical centers and teaching hospitals. She currently serves on the board for the AMSA Foundation and Universities Allied for Essential Medicines North America. As of last year, she served as co-Chair for the Doctors for America Drug Affordability Action Team and currently leads the re-established FDA Task Force.